# Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

> **NCT07514936** · PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Elderly Patients

## Interventions

- **DRUG:** the standard "3+7" regimen
- **DRUG:** Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte

## Key facts

- **NCT ID:** NCT07514936
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-18
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07514936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07514936, "Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07514936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*